Silencing hepatic complement factor B inhibits alternative pathway activation and attenuates arthritis in CAIA model
Year: 2026
Type: article
Abstract: with downstream pharmacologic and therapeutic effects, support the clinical development of AZD6912, and highlight the potential of GalNAc-siRNA therapeutics in immune-mediated diseases.
Authors: Teneema Kuriakose, Kristi Moore, Natalie Pursell, Utsav Saxena, Feiran Zhang, Henryk Dudek, Jihye Park, Nicole Spiegelman, Wei Zhou, Cecilia S. Leung, Cheng Lai, Girish Chopda, Lucie Bertrand, Mia Collins, T Scott Manetz, Sebastian Prill, Jennifer Y. Tan, Kim Clarke, Nicola Guzzi, Eden Hicks, Gabriel Wong, Patrick Riley, Kyriakos V. Konstantinidis, David Close, Susan Faas, Melissa Lasaro, Gary P. Sims
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7221563188